Tetrahydronapthyridine Orexin Receptor Antagonists
The present invention is directed to tetrahydronapthyridine and tetrahydropyridopyrazine compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
1 . A compound of the formula I:
wherein:
A is selected from the group consisting of phenyl, napthyl and heteroaryl;
B is selected from the group consisting of phenyl, napthyl and heteroaryl;
X is —CH— or N;
Y is —CH— or N, with the proviso that at least one of X and Y is N;
R 1a , R 1b and R 1c may be absent if the valency of A does not permit such substitution and are independently selected from the group consisting of:
(1) hydrogen,
(2) halogen,
(3) hydroxyl,
(4) —(C═O) m -O n -C 1-6 alkyl, where m is 0 or 1, n is 0 or 1 (wherein if m is 0 or n is 0, a bond is present) and where the alkyl is unsubstituted or substituted with one or more substituents selected from R 13 ,
(5) —(C═O) m -O n -C 3-6 cycloalkyl, where the cycloalkyl is unsubstituted or substituted with one or more substituents selected from R 13 ,
(6) —(C═O) m -C 2-4 alkenyl, where the alkenyl is unsubstituted or substituted with one or more substituents selected from R 13 ,
(7)—(C═O) m -C 2-4 alkynyl, where the alkynyl is unsubstituted or substituted with one or more substituents selected from R 13 ,
(8) —(C═O) m -O n -phenyl or —(C═O) m -O n -napthyl, where the phenyl or napthyl is unsubstituted or substituted with one or more substituents selected from R 13 ,
(9)—(C═O) m -O n -heterocycle, where the heterocycle is unsubstituted or substituted with one or more substituents selected from R 13 ,
(10) —(C═O) m -NR 10 R 11 , wherein R 10 and R 11 are independently selected from the group consisting of:
(a) hydrogen,
(b) C 1-6 alkyl, which is unsubstituted or substituted with R 13 ,
(c) C 3-6 alkenyl, which is unsubstituted or substituted with R 13 ,
(d) C 3-6 alkynyl, which is unsubstituted or substituted with R 13 ,
(e) C 3-6 cycloalkyl which is unsubstituted or substituted with R 13 ,
(f) phenyl, which is unsubstituted or substituted with R 13 , and
(g) heterocycle, which is unsubstituted or substituted with R 13 ,
(11) —S(O) 2 —NR 10 R 11 ,
(12) —S(O) q —R 12 , where q is 0, 1 or 2 and where R 12 is selected from the definitions of R 10 and R 11 ,
(13) —CO 2 H,
(14) —CN, and
(15) —NO 2 ;
R 2a , R 2b and R 2c may be absent if the valency of B does not permit such substitution and are independently selected from the group consisting of:
(1) hydrogen,
(2) halogen,
(3) hydroxyl,
(4) —(C═O) m -O n -C 1-6 alkyl, where the alkyl is unsubstituted or substituted with one or more substituents selected from R 13 ,
(5) —(C═O) m -O n -C 3-6 cycloalkyl, where the cycloalkyl is unsubstituted or substituted with one or more substituents selected from R 13 ,
(6) —(C═O) m -C 2-4 alkenyl, where the alkenyl is unsubstituted or substituted with one or more substituents selected from R 13 ,
(7)—(C═O) m -C 2-4 alkynyl, where the alkynyl is unsubstituted or substituted with one or more substituents selected from R 13 ,
(8) —(C═O) m -O n -phenyl or —(C═O) m -O n -napthyl, where the phenyl or napthyl is unsubstituted or substituted with one or more substituents selected from R 13 ,
(9) —(C═O) m -O n -heterocycle, where the heterocycle is unsubstituted or substituted with one or more substituents selected from R 13 ,
(10) —(C═O) m -NR 10 R 11 ,
(11) —S(O) 2 —NR 10 R 1i ,
(12) —S(O) q -R 12 ,
(13) —CO 2 H,
(14) —CN, and
(15) —NO 2 ;
R 3 is selected from hydrogen, C 1-6 alkyl and C 3-6 cycloalkyl, which is unsubstituted or substituted with one or more substituents selected from R 13 ;
R 4 is selected from hydrogen, C 1-6 alkyl and C 3-6 cycloalkyl, which is unsubstituted or substituted with one or more substituents selected from R 13 ;
R 5 and R 6 are independently selected from hydrogen, C 1-6 alkyl, and C 3-6 cycloalkyl;
R 13 is selected from the group consisting of:
(1) hydroxyl,
(2) halogen,
(3) C 1-6 alkyl,
(4) —C 3-6 cycloalkyl,
(5) —O-C 1-6 alkyl,
(6) —O(C═O)—C 1-6 alkyl,
(7) —NH 2 ,
(7) —NH-C 1-6 alkyl,
(8) phenyl,
(9) heterocycle,
(10) —CO 2 H, and
(11) —CN;
or a pharmaceutically acceptable salt thereof.
2 . The compound of claim 1 wherein A is phenyl or pyridyl.
3 . The compound of claim 1 wherein B is phenyl.
4 . The compound of claim 1 wherein X is N and Y is —CH—.
5 . The compound of claim 1 wherein X is —CH— and Y is N.
6 . The compound of claim 1 wherein X is N and Y is N.
7 . The compound of claim 1 wherein R 1a , R 1b and R 1c are independently selected from the group consisting of:
(1) hydrogen,
(2) halogen,
(3) hydroxyl,
(4) C 1-6 alkyl, which is unsubstituted or substituted with halogen, hydroxyl or phenyl or napthyl,
(5) —O-C 1-6 alkyl, which is unsubstituted or substituted with halogen, hydroxyl or phenyl,
(6) phenyl, which is unsubstituted or substituted with halogen, hydroxyl or C 1-6 alkyl.
8 . The compound of claim 7 wherein R 1c is hydrogen, and R 1a and R 1b are independently selected from the group consisting of:
(1) hydrogen,
(2) fluoro,
(3) chloro,
(4) methyl, and
(5) trifluoromethyl.
9 . The compound of claim 1 wherein R 2a , R 2b and R 2c are independently selected from the group consisting of:
(1) hydrogen,
(2) halogen,
(3) hydroxyl,
(4) C 16 alkyl, which is unsubstituted or substituted with halogen, hydroxyl or phenyl,
(5) —O—C 1-6 alkyl, which is unsubstituted or substituted with halogen, hydroxyl or phenyl, and (6) —NH-C 1-6 alkyl, or —N(C 1-6 alkyl)(C 1-6 alkyl), which is unsubstituted or substituted with halogen.
10 . The compound of claim 9 wherein R 2c is hydrogen, and R 2a and R 2b are independently selected from the group consisting of:
(1) hydrogen,
(2) fluoro, and
(3) trifluoromethyl.
An embodiment of the present invention includes compounds wherein R 2a is hydrogen, R 2b is hydrogen, and R 2c is hydrogen.
11 . The compound of claim 1 wherein R 3 is C 1-6 alkyl.
12 . The compound of claim 1 wherein R 4 is hydrogen.
13 . The compound of claim 1 wherein R 5 is methyl and R 6 is methyl.
14 . A compound which is selected from the group consisting of:
2-[(5S)-2,3-dimethoxy-5-{2-[4-(trifluoromethyl)phenyl]ethyl}-7,8-dihydro-1,6-naphthyridin-6(5H)-yl]-N-methyl-2-phenylethanamide;
2-[(5S)-5-[2-(4-chlorophenyl)ethyl]-2,3-dimethoxy-7,8-dihydro-1,6-naphthyridin-6(5H)-yl]-N-methyl-2-phenylethanamide;
2-[(5S)-5-[2-(2,4-difluorophenyl)ethyl]-2,3-dimethoxy-7,8-dihydro-1,6-naphthyridin-6(5H)-yl]-N-methyl-2-phenylethanamide;
2-[(5S)-2,3-dimethoxy-5-[2-(4-methylphenyl)ethyl]-7,8-dihydro-1,6-naphthyridin-6(5H)-yl]-N-methyl-2-phenylethanamide;
2-[(8S)-2,3-dimethoxy-8-{2-(4-(trifluoromethyl)phenyl]ethyl}-5,8-dihydro-1,7-naphthyridin-7(6H)-yl]-N-methyl-2-phenylethanamide;
2-[(5S)-2,3-dimethoxy-5-{2-[4-(trifluoromethyl)phenyl]ethyl}-7,8-dihydropyrido[3,4-b]pyrazin-6(5H)-yl]-N-methyl-2-phenylethanamide;
2-[(5S)-2,3-dimethoxy-5-{2-[4-(trifluoromethyl)phenyl]ethyl}-7,8-dihydro-1,6-naphthyridin-6(5H)-yl]-N-methyl-2-phenylethanamide;
(2R)-2-[(5S)-5-[2-(4-chlorophenyl)ethyl]-2,3-dimethoxy-7,8-dihydro-1,6-naphthyridin-6(5H)-yl]-N-methyl-2-phenylethanamide;
(2R)-2-[(5S)-5-[2-(2,4-difluorophenyl)ethyl]-2,3-dimethoxy-7,8-dihydro-1,6-naphthyridin-6(5H)-yl]-N-methyl-2-phenylethanamide;
(2R)-2-[(5S)-2,3-dimethoxy-5-[2-(4-methylphenyl)ethyl]-7,8-dihydro-1,6-naphthyridin-6(5H)-yl]-N-methyl-2-phenylethanamide;
(2R)-2-[(8S)-2,3-dimethoxy-8-{2-[4-(trifluoromethyl)phenyl]ethyl}-5,8-dihydro-1,7-naphthyridin-7(6H)-yl]-N-methyl-2-phenylethanamide; and
(2R)-2-[(5S)-2,3-dimethoxy-5-{2-[4-(trifluoromethyl)phenyl]ethyl}-7,8-dihydropyrido[3,4-b]pyrazin-6(5H)-yl]-N-methyl-2-phenylethanamide;
or a pharmaceutically acceptable salt thereof.
15 . A pharmaceutical composition which comprises an inert carrier and a compound of claim 1 or a pharmaceutically acceptable salt thereof.
16 . (canceled)
17 . (canceled)
18 . A method for enhancing the quality of sleep in a mammalian patient in need thereof which comprises administering to the patient a therapeutically effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof.
19 . A method for treating insomnia in a mammalian patient in need thereof which comprises administering to the patient a therapeutically effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof.
20 . A method for treating or controlling obesity in a mammalian patient in need thereof which comprises administering to the patient a therapeutically effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof.